title: Cisplatin and teniposide chemotherapy for advanced non-small cell lung cancer.
abstract: 30 patients with advanced non-small cell lung cancer were treated with cisplatin 80 mg/m2, day 1, and teniposide 100 or 120 mg/m2, days 1, 3 and 5, every 3 weeks. Myelotoxicity, nausea and vomiting and alopecia were the main side-effects. 8 patients of 26 evaluable had partial responses (31%): 6 had received 120 mg/m2 teniposide and 2 had received 100 mg/m2 teniposide. Overall median survival time was 251 days. Myelotoxicity was significantly lower in patients who received 100 mg/m2 teniposide. Although the number of patients is small and they were not randomly assigned to the two different teniposide doses, it appears that higher dose of teniposide determined a greater degree of myelotoxicity, and also a higher response rate.
authors.affiliation: Department of Oncology, Free University Hospital, Amsterdam, The Netherlands.
authors.forename: V
authors.initials: V
authors.lastname: Iberti
authors.forename: M
authors.initials: M
authors.lastname: Donadio
authors.forename: G
authors.initials: G
authors.lastname: Giaccone
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D013713:Teniposide / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D013713:Teniposide; D002945:Cisplatin